Trials / Recruiting
RecruitingNCT05822037
CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
Exploratory Study to Assess the Safety and Efficacy of CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 6 (estimated)
- Sponsor
- The First Affiliated Hospital of Soochow University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, single arm study to evaluate the safety and tolerability of treatment with CT0594CP CAR-T Cells in patients with relapsed and/or refractory multiple myeloma or Plasma Cell Leukemia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CT0594CP | Cell injection |
Timeline
- Start date
- 2023-04-12
- Primary completion
- 2026-04-29
- Completion
- 2026-04-29
- First posted
- 2023-04-20
- Last updated
- 2023-04-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05822037. Inclusion in this directory is not an endorsement.